Bowenoid papulosis of the genitalia successfully treated with topical tazarotene : AAreport of two cases

Indian Journal of Dermatology

Volumn 54, Issue 3, 2009, Pages 283-286

  Shastry, Veeranna ^a   Betkerur, Jayadev ^a   Kushalappa, ^a  

^a JSS Hospital   (India)

Author keywords

Bowenoid papulosis; Human papilloma virus; Tazarotene

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; STEROID; TAZAROTENE;

ADULT; ARTICLE; BOWENOID PAPULOSIS; CASE REPORT; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENITAL SYSTEM DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; MALE; PAPULE; PENIS; RECURRENT DISEASE; RETREATMENT; SCROTUM; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; TREATMENT OUTCOME;

EID: 70349427199     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.55643     Document Type: Article

References (15)

1. Toro JR, Sanchez S, Turiansky G Blauvelt A. Topical cidofovir for the treatment of dermatologic conditions: Verruca, condyloma, intraepithelial neoplasis, herpes simplex and its potential use in smallpox. Dermatol Clin 2003;21:303-304
2. Duncan KO, Geisse JK, Leffell DJ. Epithelial precancerous lesions. In: Wolff K, Goldsmith lA, Katz SI, et al. editors. Fitzpatrick's dermatology in general medicine. 7th ed. vol 1. New York: McGraw Hill Medical; 2008. p. 1007-1027
3. Bunker CB, Neil SM. The genital, perianal and umbilical regions In: Burns T, Breathnach S, Cox N, Griffith C, editors. Rook's Textbook of dermatology. 7th ed. Oxford: Blackwell Science; 2004. p. 68.35-68.36.
4. Shwartz RA, Janniger CK. Bowenoid papulosis. J Am Acad Dermatol 1991;24:261.
5. Xu X, Erickson L, Chen L, Elder DE. Diseases caused by viruses. In: Elder DE, Elenitsas R, Murphy GF, Johnson B Jr, Xu X, editors, Lever's histopathology of skin. 10th ed. Philadelphia: Lippincott-Williams and Wilkins; 2009. p. 65-67
6. Weitzner JM, Fields KW, Robinson MJ. Pediatric bowenoid papulosis: Risks and management. Pediatr Dermatol 1987;6:303.
7. Gimeno E, Vilata JJ, Sanchez JL, Lloreta A, Fortea JM. Bowenoid papulosis: Clinical and histological study of 8 cases. Genitourin Med 1987;63:109-113
8. Baldwin PJ, Vanden Burg SH, Boswell CM. Vaccinia expressed HPV 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasis. Clin Cancer Res 2003;9:5205-5213
9. Barbarot S, Acher-Chenebaux A, Stalder JF. Topical tazarotene for severe congenital icthyosis. Ann Dermatol Venereol 2006;133:66-67
10. Rajiv S, Rakesh SV. Icthyosis bullosa of Siemens: Response to topical tazarotene. Indian J Dermatol Venereal Leprol 2006;72:43-46
11. Deliduka SB, Kwong PC. Treatment of nevus comedonicus with topical tazarotene and calcipotrien. J Drugs Dermatol 2004;3:674-676
12. Brazzelli V, Prestinari F, Barbagallo T, Vasallo C, Agozzino M. Linear Darrier's disease successfully treated with 0.1% tazarotene gel 'short contact' treatment. Eur J Dermatol 2006;16:59-61.
13. Boyd J, Sloan S, Meffer T. Elephentiasis nostrum verrucosa of the abdomen: Clinical results with tazarotene. J Drugs Dermatol 2004;3:446-448
14. Peris K, Fargnoli MC, Chimenti S. Preliminary observation on the use of topical tazarotene to treat BCC. N Engl J Med 1999;341:1707-1708
15. Bardazzi F, Bianchi F, Parente G. A pilot study on the use of topical tazarotena to treat squamous cell carcinoma in situ. J Am Acad Dermatol 2005;52:1102-1104